|
|||||
|
|
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations |
|
| Authors: | Richard J. Lin Caleb Ho Patrick D. Hilden Juliet N. Barker Sergio A. Giralt Paul A. Hamlin Ann A. Jakubowski Hugo R. Castro-Malaspina Kevin S. Robinson Esperanza B. Papadopoulos Miguel-Angel Perales Craig S. Sauter |
| Affiliation: | 1. Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA;2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA;3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA;4. Adult BMT Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA Weill Cornell Medical College, New 5. York, NY, USA;6. Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA Weill Cornell Medical College, New |
| Abstract: | TP53 alterations portend extremely poor prognosis in patients with mantle cell lymphoma treated with standard treatment modalities. We reviewed outcomes of 42 patients with available TP53 status who had received a reduced-intensity or non-myeloablative allogeneic haematopoietic cell transplant at our institution. We demonstrated a 2-year overall survival and progression-free survival of 78% [95% confidence interval (CI) 60–88] and 61% (95% CI 43–75), respectively. The 2-year cumulative incidences of relapse and non-relapse mortality were 19% and 20%, respectively. Importantly, there is no significant difference among patients with and without TP53 alterations, suggesting for the first time a beneficial treatment modality for these high-risk patients. |
| Keywords: | allogeneic hematopoietic cell transplant mantle cell lymphoma TP53 |